Cardio Catch-Up: Procyrion Raises Nearly $60M As Aortix Creeps Closer To Clinic
The Houston-based cardiovascular device developer has secured renewed support from its investors to fund its pivotal trial of Aortix, a device designed to treat patients suffering from often-fatal, difficult to treat cardiorenal syndrome.
You may also be interested in...
To help patients suffering from cardiorenal syndrome, an undertreated illness, Procyrion has embarked on the first in-human trials of its Aortix mechanical circulatory support device.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Less than a month after it sold off its reproductive health assets, Invitae has filed for bankruptcy. That will not come as a surprise to anyone following the company.